Moderna, Inc. (MRNA) $59.17
Moderna is attempting a violent trend reversal after a brutal 20% monthly slide, but a wall of bearish technical gaps stands between this bounce and a true recovery.
52-wk High $85.6
📌 Investment Snapshot
- Current price of $59.17 sits 30.9% below the 52-week high of $85.60.
- Q2 2026 revenue collapsed to $0.14B with a deep EPS loss of -$1.97.
- Short interest remains elevated at 16.1% of float, suggesting a high-conviction bearish cohort.
- Wall Street consensus target of $50.84 implies the stock is currently overvalued by 14%.
⏳ WAIT
Moderna is trapped in a structural downtrend despite today’s relief rally. The stock faces heavy overhead resistance from three unfilled bearish gaps and a declining SMA50.
| 📍 Entry Zone | $47.26 or below | 🛑 Stop-Loss | $44.50 |
| 📋 Adjust If | Moderna reclaims $66.00 on 1.5x average volume. | ||
The Investment Case — Why Now?
The narrative surrounding Moderna has shifted from pandemic savior to a speculative pipeline play over the last 90 days. Revenue has cratered from $1.0B in late 2025 to a mere $0.14B in the most recent quarter, forcing the market to re-evaluate the company’s cash burn. Management’s ability to bridge the gap until their RSV and flu pipelines reach commercial scale is now the primary driver of volatility.
Free cash flow remains a significant concern with a -$0.6B burn in the latest quarter alone. While the $23.6B market cap reflects some optimism for the mRNA platform, the 16.1% short interest signals that many traders expect further dilution or disappointing clinical data. Can Moderna’s non-COVID pipeline generate enough revenue to offset the $7.98 annual EPS loss before cash reserves dwindle?
If the current cash burn persists, at what point does the market stop valuing the pipeline and start pricing in a liquidity crunch?
🤔 If the current cash burn persists, at what point does the market stop valuing the pipeline and start pricing in a liquidity crunch?
🏢 Company Overview
| Detail | Value |
|---|---|
| Sector | Healthcare |
| Industry | Biotechnology |
| President | Stephen Hoge |
| Short Interest | 16.1% |
Open chart on TradingView →
📈 Price Action & Technicals
Inside VA
Buy-side Sweep at $53.35
The price action remains decisively bearish as MRNA trades below its SMA50 of $59.30, despite today’s 8.4% jump. This moving average has acted as a ceiling for the past month, and a failure to close above it will likely invite fresh selling pressure. Support is firmly established at the SMA200 of $45.59, which aligns closely with the anchored VWAP.
Technical indicators present a conflicted picture with the RSI at a neutral 49.4 while the ADX screams a high-intensity trend at 59.3. The -DI remains significantly above the +DI, confirming that the path of least resistance is still downward. A MACD crossover is not yet visible, suggesting this bounce lacks the momentum for a sustained trend change.
Volume Profile analysis reveals the Point of Control (POC) at $51.41, a level that served as a magnet during the recent sell-off. Price is currently testing the upper boundary of the Value Area ($60.27). If buyers cannot push through this zone, a reversion to the POC is the most probable outcome.
Bollinger Bands show the stock is currently trading in the middle of its range, having recovered from the lower band at $49.75. However, three unfilled bearish Fair Value Gaps (FVG) between $60.83 and $65.95 represent significant ‘supply walls.’ These zones must be cleared before any long-term bullish thesis can be validated.
Historically, Moderna has shown a tendency for ‘dead cat bounces’ following earnings misses before making new lows. Today’s 1.31x volume ratio is encouraging but insufficient to confirm institutional accumulation. We expect a period of consolidation between $50 and $60 before the next major directional move.
⚖ Peer P/E Comparison
| Ticker | Company | P/E (TTM) |
|---|---|---|
| MRNA | Moderna, Inc. | N/A |
| BNTX | BioNTech SE | 24.5x |
| PFE | Pfizer Inc. | 12.8x |
| SPY | S&P 500 Avg | 21.4x |
💰 Earnings Deep Dive
| Period | Revenue | EPS | YoY |
|---|---|---|---|
| Q2 2026 | $0.14B | -$1.97 | -86% |
| Q1 2026 | $0.39B | -$3.40 | -78% |
| Q4 2025 | $0.68B | -$2.11 | -62% |
| Q3 2025 | $1.00B | -$0.51 | -45% |
Moderna reported a free cash flow of -$0.6B in the latest quarter, highlighting the intense capital requirements of its late-stage clinical trials.
Revenue is in a freefall, declining for four consecutive quarters as COVID-19 vaccine demand evaporates. The company is now entirely dependent on its ability to commercialize new mRNA applications in oncology and rare diseases.
🚀 Growth Drivers — What Moves the Stock
- RSV Vaccine Launch 🟡 Priced In — The rollout of mRESVIA is the critical near-term revenue bridge to offset declining COVID sales.
- Oncology Pipeline 🟢 Upside Surprise — Positive Phase 3 data for individualized neoantigen therapy (INT) could trigger a massive re-rating.
- Next-Gen Flu Program 🟢 Upside Surprise — Combination vaccines (Flu+COVID) aim to capture the seasonal market more efficiently than competitors.
🤔 With revenue down 86% year-over-year, can the RSV launch realistically fill a billion-dollar hole in the balance sheet?
🏦 Smart Money & Institutional Positioning
13F Holdings
| Institution | Shares (K) |
|---|---|
| FMR, LLC | 45,672 |
| Blackrock Inc. | 29,635 |
| Vanguard Capital Management LLC | 22,872 |
Holdings reflect most recent 13F (45-day lag).
Insider Transactions
| Name | Title | Date | Type | Shares |
|---|---|---|---|---|
| HOGE STEPHEN | President | 2026-07-15 | Sale | 53,336 |
| MOCK JAMES M | CFO | 2026-07-02 | Sale | 1,452 |
Short Interest
| Short % Float | Days to Cover |
|---|---|
| 16.1% | 5.2 |
⚠ Key Risk Factors
~$5B impact
~$3B impact
~$1.5B impact
🎯 Guidance & Wall Street View
Management has focused on reducing R&D expenses while prioritizing the launch of the RSV vaccine to stabilize the top line by 2027.
| High Target | Mean Target | Low Target | Analysts | Consensus |
|---|---|---|---|---|
| $79.00 | $50.84 | $25.00 | 19 | Hold |
| Firm | Rating | Target | Date | Action |
|---|---|---|---|---|
| Citigroup | Neutral | $51.00 | 2026-08-03 | Maintained |
| B of A Securities | Underperform | $35.00 | 2026-07-07 | Maintained |
Analysts are largely skeptical, with the mean target sitting 14% below the current market price, suggesting the recent rally is overextended.
Open chart on TradingView →
📊 Bull vs Bear — Probability-Weighted Scenarios
🐂 Bull Case
- RSV vaccine adoption exceeds expectations in the senior demographic.
- Individualized cancer vaccine data shows superior efficacy vs. standard care.
📊 Base Case
Moderna stabilizes revenue through seasonal combination shots but continues to burn cash through 2027.
🐻 Bear Case
- Clinical trial failures for the flu pipeline lead to massive write-downs.
- Dilutive capital raise becomes necessary to fund operations.
🎯 Investor Action Plan — By Profile
The stock is currently trading into a cluster of bearish Fair Value Gaps ($60-$65) and a declining SMA50. Risk/reward is poor for a long entry here; wait for a rejection and retest of $51.41.
Despite the 8% bounce, the fundamental picture is deteriorating with an 86% revenue decline. Wait for RSI to dip below 35 or for the stock to touch the anchored VWAP at $47.26 before building a position.
If you own MRNA for the mRNA platform’s long-term potential, stay the course but do not add here. The technical confluence score of 70 is moderate, but the lack of a Golden Cross and negative EPS make it a high-risk hold.
If you’re interested in the Healthcare sector, also read:
❓ Investor FAQ — People Also Ask
Q: Why did Moderna stock jump 8% today?
The jump appears to be a technical relief rally from oversold conditions, supported by a buy-side liquidity sweep at $53.35, rather than a fundamental shift.
Q: Is Moderna's dividend safe?
Moderna does not currently pay a dividend, as it prioritizes reinvesting its dwindling cash reserves into its R&D pipeline.
Q: What is the key level to watch for MRNA?
The $60.27 level is the Value Area High; a failure to break and hold above this price suggests a return to the $51.41 Point of Control.
📖 New to these terms? P/E Ratio · Free Cash Flow · Insider Signals · Stop-Loss · RSI
📊 Want to verify if this analysis still holds?
📋 Disclaimer
This analysis is for informational purposes only and does not constitute financial advice. Biotech stocks carry extreme risk due to clinical trial volatility.
All active positions and their real-time performance are tracked on our Investment Log.
#MRNA #Moderna #Biotech #StockMarket #Investing #WallStreet #mRNA